AdAlta Ltd (ASX: 1AD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

AdAlta Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.49 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 595.62 million
Earnings per share -0.013
Dividend per share N/A
Year To Date Return 4.17%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • AdAlta Ltd (ASX: 1AD)
    Latest News

    woman in lab coat conducting testing representing biotech
    Share Market News

    AdAlta (ASX:1AD) share price rockets 31% on United States FDA update

    The AdAlta Ltd (ASX:1AD) share price is rocketing today following the positive news on its drug trials. Here's all the…

    Read more »

    1AD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About AdAlta Ltd

    AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

    1AD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Jun 2024 $0.03 $0.00 0.00% 250,000 $0.03 $0.03 $0.03
    20 Jun 2024 $0.03 $0.00 0.00% 343,532 $0.03 $0.03 $0.03
    19 Jun 2024 $0.03 $0.00 0.00% 34,000 $0.03 $0.03 $0.03
    18 Jun 2024 $0.03 $0.00 0.00% 9,160 $0.03 $0.03 $0.03
    17 Jun 2024 $0.03 $0.00 0.00% 760,645 $0.03 $0.03 $0.03
    14 Jun 2024 $0.03 $0.00 0.00% 20,000 $0.03 $0.03 $0.03
    13 Jun 2024 $0.03 $0.00 0.00% 314,798 $0.03 $0.03 $0.03
    12 Jun 2024 $0.03 $0.00 0.00% 80,000 $0.03 $0.03 $0.03
    11 Jun 2024 $0.03 $0.00 0.00% 10,646 $0.03 $0.03 $0.03
    07 Jun 2024 $0.03 $0.00 0.00% 190,000 $0.03 $0.03 $0.03
    05 Jun 2024 $0.03 $0.00 0.00% 151,798 $0.03 $0.03 $0.03
    04 Jun 2024 $0.03 $0.00 0.00% 15,000 $0.03 $0.03 $0.03
    03 Jun 2024 $0.03 $0.00 0.00% 146,228 $0.03 $0.03 $0.03
    31 May 2024 $0.03 $0.00 0.00% 419,697 $0.03 $0.03 $0.03
    30 May 2024 $0.03 $0.00 0.00% 339,693 $0.03 $0.03 $0.03
    29 May 2024 $0.03 $0.00 0.00% 1,028,031 $0.03 $0.03 $0.03
    28 May 2024 $0.03 $0.00 0.00% 629,590 $0.03 $0.03 $0.03
    27 May 2024 $0.03 $0.00 0.00% 1,129,341 $0.03 $0.03 $0.03

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Dec 2023 David Fuller Issued 1,750,000 $22,092
    Issue of options. Black-Scholes valuation
    19 Dec 2023 Paul MacLeman Issued 2,800,000 $35,347
    Issue of options. Black-Scholes valuation, typo error
    19 Dec 2023 Timothy Oldham Issued 500,000 $10,000
    Issue of securities.
    19 Dec 2023 Timothy Oldham Issued 5,600,000 $70,694
    Issue of options. Black-Scholes valuation
    19 Dec 2023 Timothy Oldham Issued 500,000 $12,500
    Issue of options.
    19 Dec 2023 Robert Peach Issued 1,750,000 $22,092
    Issue of options. Black-Scholes valuation

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr David Fuller Non-Executive Director Jul 2020
    Mr Fuller has more than 30 years of experience in pre-clinical, clinical development, medical and regulatory affairs with specialisations in early phase development and oncology. He has led five product approvals in the United States (US) and European Union (EU) for orphan and major market products, together with multiple Regulatory Agency (US/EU) interactions including Investigational New Drug (IND) applications. David has designed and executed Phase I - III studies in US, EU and Asia across multiple therapeutic areas. David is currently Chief Medical Officer for Aucentra Therapeutics and is also Chair of EpiAxis Therapeutics Pty Ltd.
    Dr Paul MacLeman Non-Executive ChairmanNon-Executive Director Oct 2019
    Mr MacLeman has more than 25 years of experience across all phases of the life sciences sector. With a career-spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, Paul has expertise in capital management, business development, technology commercialisation and sales & marketing globally. Paul has launched products using in-house and outsourced sales staff in Australia and the US. He has founded life sciences start-ups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. Paul has previously served as Chairman, Director or Managing Director/CEO of several VC funded, ASX, NASDAQ, CSE and TSX listed companies and has driven a number of IPOs. Paul Chaired the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC for 10 years prior to the establishment of the new Jobs and Skills Councils and advises the new formed Manufacturing Industry Skills Alliance. He is also an advisor to PharmaVentures plc. (Oxford, UK) and serves on a number of other NFP and government advisory groups. He currently Chairs or is a Non-Executive Director of a number of public unlisted and private companies.
    Dr Timothy Oldham Managing DirectorChief Executive Officer Oct 2019
    Mr Oldham has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a focus on biologics, cell and gene therapies and pharmaceutical products. He was Executive Leader of Tijan Ventures, a business focused on growing life sciences companies through advisory and interim CEO, executive and non-executive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. Prior to this, Tim was an engagement manager with McKinsey & Company. He currently serves as a Director of BioMelbourne Network Inc
    Dr Robert Peach Non-Executive Director Nov 2016
    Mr Peach has 30 years of drug discovery and development experience in the Pharmaceutical and Biotechnology industry. In 2009 he co-founded Receptos, becoming Chief Scientific Officer and raising US$59M in venture capital and US$800M in an IPO and three subsequent follow-on offerings. In August 2015 Receptos was acquired by Celgene for $7.8B. Robert held executive and scientific positions in other companies including Apoptos, Biogen Idec, IDEC and Bristol- Myers Squibb, supporting in-licensing, acquisition and venture investments. His drug discovery and experience in autoimmune and inflammatory diseases, and cancer has resulted in drugs entering clinical trials and 4 registered drugs. Robert is the co-author of 75 publications and book chapters, and 17 patents.
    Mr Cameron Jones Chief Financial OfficerCompany Secretary May 2017
    -
    Cameron Jones Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 89,147,577 20.19%
    Fletcher Meurs Investments Pty Ltd 27,029,924 6.12%
    Yclp Pty Ltd <Yclp A/C> 27,029,924 6.12%
    Sacavic Pty Ltd <Morris Super Fund A/C> 22,317,236 5.05%
    Meurs Holdings Pty Ltd <P&M Meurs Superannuation A/C> 20,123,655 4.56%
    Radiata Foundation Ltd 15,560,519 3.52%
    Ms Chunyan Niu 14,800,000 3.35%
    Hb Biotechnology Ltd 6,534,949 1.48%
    Skiptan Pty Ltd <P&M Meurs Family A/C> 6,440,589 1.46%
    Mr Kevin John Cairns & Mrs Catherine Valerie Cairns <Cairns Family Super A/C> 4,400,000 1.00%
    Citycastle Pty Ltd 4,302,320 0.97%
    Mr John Okroglic 3,447,080 0.78%
    10 Bolivianos Pty Ltd 3,306,768 0.75%
    La Trobe University 3,041,330 0.69%
    Scintilla Strategic Investments Limited 3,000,000 0.68%
    Mr Iain Ross 2,880,000 0.65%
    Bauldia Pty Ltd <Bonaventure Super Fund A/C> 2,817,874 0.64%
    Azzurra Investments Pty Ltd 2,800,000 0.63%
    Castle Manor Pty Ltd <Arrendene Holdings A/C> 2,503,904 0.57%
    Jagen Pty Ltd 2,500,000 0.57%
    Stuart Consulting Group Pty Ltd 2,500,000 0.57%
    Mrs Gwen Murray Pfleger <Pfleger Family A/C> 2,400,000 0.54%

    Profile

    since

    Note